Pinnacle Associates’s Caribou Biosciences CRBU Stock Holding History

Pinnacle Associates’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$16.4K	Hold	12,903	–	–	﹤0.01%	956
2026 Q2	$22.7K	Hold	12,903	–	–	﹤0.01%	967
2026 Q1	$24.5K	Hold	12,903	–	–	﹤0.01%	954
2025 Q4	$20.5K	Hold	12,903	–	–	﹤0.01%	931
2025 Q3	$30.1K	Hold	12,903	–	–	﹤0.01%	862
2025 Q2	$16.3K	Hold	12,903	–	–	﹤0.01%	845
2025 Q1	$11.8K	Hold	12,903	–	–	﹤0.01%	823
2024 Q4	$20.5K	Hold	12,903	–	–	﹤0.01%	832
2024 Q3	$73.9K	Hold	12,903	–	–	﹤0.01%	786
2024 Q2	$21.2K	Hold	12,903	–	–	﹤0.01%	810
2024 Q1	$66.3K	Hold	12,903	–	–	﹤0.01%	821
2023 Q4	$73.9K	Hold	12,903	–	–	﹤0.01%	800
2023 Q3	$61.7K	Hold	12,903	–	–	﹤0.01%	795
2023 Q2	$54.8K	Hold	12,903	–	–	﹤0.01%	804
2023 Q1	$68.5K	Hold	12,903	–	–	﹤0.01%	756
2022 Q4	$81K	Hold	12,903	–	–	﹤0.01%	740
2022 Q3	$136K	Hold	12,903	–	–	﹤0.01%	711
2022 Q2	$70K	Buy	+12,903	New	+$98.6K	﹤0.01%	731

Other funds holding CRBU

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $45.2B AUM 20.72% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

MAM

Milestone Asset Management Pittsburgh, Pennsylvania $631M AUM 19.94% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Prime Capital Investment Advisors Overland Park, Kansas $10.2B AUM 17.74% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Pinnacle Associates's CRBU Position: Q3 2026 in Review

Pinnacle Associates held its Caribou Biosciences (CRBU) position steady in Q3 2026 at 12,903 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #956.

Pinnacle Associates first reported a position in CRBU in Q2 2022 and has held it in 18 quarters since. The position peaked at $136K in Q3 2022. 56 funds tracked by Wall St. Rank hold CRBU as of Q3 2026.

Pinnacle Associates held 12,903 shares of Caribou Biosciences worth $16.4K as of Q3 2026.
Pinnacle Associates left its Caribou Biosciences share count unchanged in Q3 2026.
Caribou Biosciences made up ﹤0.01% of Pinnacle Associates's portfolio in Q3 2026, its #956 holding.
Pinnacle Associates first reported a position in Caribou Biosciences in Q2 2022 and has held it in 18 quarters since.
Pinnacle Associates's Caribou Biosciences position peaked at $136K in Q3 2022.
56 funds tracked by Wall St. Rank held Caribou Biosciences as of Q3 2026.

Based on Pinnacle Associates's 13F filing for Q3 2026, filed 20 Oct 2026.